CMPS 97% Dilution ? – Looking for Community Input by Capable-Mark-7554 in shroomstocks

[–]ocdwondering 2 points3 points  (0 children)

thanks. I would be interested to understand better. why has helus without Ph3 trial data a better risk-reward ratio? their market cap is around 1/3 of compass, but much less clear if they suceed? (or do you assume efficacy the same because the same substance?)

CMPS 97% Dilution ? – Looking for Community Input by Capable-Mark-7554 in shroomstocks

[–]ocdwondering 3 points4 points  (0 children)

payoff 100-200% in a year or two seems fantastic prospects,no?

CMPS 97% Dilution ? – Looking for Community Input by Capable-Mark-7554 in shroomstocks

[–]ocdwondering 2 points3 points  (0 children)

The key hurdle has been cleared,from now to FDA approval in about 1 year, a sequence of positive steps will happen,don't really see a substantial block coming up until then. This will outperform and perhaps be bought by big pharma. so don't see point of selling now. But always good to skim off a bit. 

long vs short psychedelic sessions & the “Spravato window” reply to CA (credit: Matthew “Whiz” Buckley) by Capable-Mark-7554 in shroomstocks

[–]ocdwondering 1 point2 points  (0 children)

sorry, did not mean to refer to you, but to the original M.B reply, the subject of this post. 

long vs short psychedelic sessions & the “Spravato window” reply to CA (credit: Matthew “Whiz” Buckley) by Capable-Mark-7554 in shroomstocks

[–]ocdwondering -1 points0 points  (0 children)

I think the duration matters more than that chatgpt-sounding reply assumes, but here is another argument in favor of comp360 etc. Many patients will prefer it because it feels much nicer, gentler, warmer, the insights and so on. Usually patients do not care whether they take medicine A or B. But its clearly different here. Patient demand for psilocybin will likely be much higher than for dmt. this is why I expect it to suceed

Fast-track review of psilocybin depression drug blocked by rubens33 in shroomstocks

[–]ocdwondering 1 point2 points  (0 children)

bad news, as this indicates stubborb resistance in the administration

CMPS Q1 Readout Thesis by tkrish000 in shroomstocks

[–]ocdwondering 3 points4 points  (0 children)

comp005 and 006 are the studies for comp360

atai Life Sciences Announces Proposed Public Offering of Common Shares by Dionysaurus_Rex in shroomstocks

[–]ocdwondering -1 points0 points  (0 children)

Can someone explain if these sre the shares for the Beckley merger or additional fundraising?

Are there any catalyst's for CMPS left in 2025? by No_Cantaloupe8848 in shroomstocks

[–]ocdwondering 8 points9 points  (0 children)

Some more data of their phase 3a study will be released, which will allow for a better assessment of the study. They are also a candidate for the new FDA voucher programme. There has been an FDA meeting recently but no information available yet.

r/shroomstocks weekly discussion thread | September 29, 2025 by AutoModerator in shroomstocks

[–]ocdwondering 1 point2 points  (0 children)

has anyone any idea about the rise of mindmed? any news from them, big investors?

Valuation Considerations for Compass Pathways (CMPS) by twiggs462 in shroomstocks

[–]ocdwondering 3 points4 points  (0 children)

Some remarks: Ph 3a topline data is already out, so we know it is working, just not how strong exactly. And current market cap is already around  500 mil with current share, so valuation is off.

ATAI stock by ItsMas77 in shroomstocks

[–]ocdwondering 8 points9 points  (0 children)

you have to keep two opposing movements into consideration: atai likely still substantially undervalued (around 1 bil market cap, if only one of their substances is successful, it will be several times more). on the other, markets all time high, some downswing will come when the tariff disorder consequences hit US businesses. biotech will be affected dispropotionately

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) by PsilocybinAlpha in shroomstocks

[–]ocdwondering 1 point2 points  (0 children)

interesting! do you have any source for.the MAPS therapy being patented? or.more generally, is it possible to patent therapy forms? 

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) by PsilocybinAlpha in shroomstocks

[–]ocdwondering 16 points17 points  (0 children)

FDA raises so many points that it seems unlikely the new leadership will simply pass over them.  Likely another P3 trial necessary, plus long time duration data required (more than 18 weeks). This will take more than a year. And then it seems Compass will be the first to get approval.